Navigation Links
New insight into protein misfolding in neurodegenerative disorders
Date:2/14/2014

Research by the University of Southampton has provided new insight into the consequence of accumulated 'misfolded proteins' in neurodegenerative disorders, such as Prion and Alzheimer's disease.

Prion and Alzheimer's disease are protein misfolding brain diseases, where genetic mutations, or more commonly, interactions between an individual's genetics and environmental influences cause functional proteins in neurons to become misfolded or misrouted. In these diseases, there is a progressive death of nerve cells in specific brain regions, which is associated with the increasing extracellular or intracellular accumulation of misfolded proteins. This leads to synapse degeneration and eventual loss of nerve cells and cognitive and behavioural conditions associated with the disease.

To increase the understanding of the disease mechanisms, the researchers, led by Dr Ayodeji Asuni from the University's Centre for Biological Sciences, compared prion disease brain tissue, which mirrors key features of Alzheimer's disease, and the brain of control mice.

They found that the degenerative process is paralleled by an increase in astrocytes a major support cell in the brain and four specific astrocytes-associated proteins: GFAP (structural protein), peroxiredoxin-6 (an antioxidant protein), EAAT-2 (glutamate transporter), and Clusterin (a chaperone protein). These are produced in greater amounts in response to the misfolding protein, perhaps to provide support and protection for neurons in the brain.

Current research has identified Clusterin as a biomarker for Alzheimer's disease and Dr Asuni's team extended their investigation to address whether Clusterin changes in the brain could be detected in the blood; such a result would have confirmed Clusterin as a potential biomarker for brain disease.

Dr Asuni says: "In contrast to observations made in Alzheimer's disease, the increased Clusterin expression in the brain was not reflected in the circulating levels of Clusterin in late-stage prion disease.

"So we caution against the assumption that plasma levels of Clusterin provide an alternate peripheral measure for the progression of brain degeneration. We believe the observations from our study in experimental conditions, in which potential confounds can be well controlled, will likely be of value in the interpretation of results from Alzheimer's disease patients."


'/>"/>

Contact: Glenn Harris
G.Harris@soton.ac.uk
44-023-805-93212
University of Southampton
Source:Eurekalert  

Related biology news :

1. New insight into an emerging genome-editing tool
2. Paper offers insights into network that plays crucial role in cell function and disease
3. Gene that influences receptive joint attention in chimpanzees gives insight into autism
4. Zebra fish fins help Oregon researchers gain insight into bone regeneration
5. Scripps Florida scientists offer new insight into neuron changes brought about by aging
6. New insights into facial transplantation
7. Elephant shark genome provides new insights into bone formation and adaptive immunity in humans
8. New research provides insight into epilepsy
9. The origin of flowers: DNA of storied plant provides insight into the evolution of flowering plants
10. Study led by NUS scientists provides new insights into cause of human neurodegenerative disease
11. Oregon scientists offer new insights on controlling nanoparticle stability
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New insight into protein misfolding in neurodegenerative disorders
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: